This site is intended for health professionals only
Thursday 27 June 2019
Share |

Topic: Drug discovery

December 15, 2017
The collaboration is centred on mRNA translation, which is a promising area of research with the potential to produce treatments that can target a fundamental characteristic of cancer cells

Cancer Research UK has announced the signing of a five-year drug-discovery collaboration between its subsidiary, Cancer Research Technology (CRT), and Celgene Corporation, to discover, develop and commercialise new anti-cancer treatments.


This arrangement represents an expansion of Cancer Research Technology’s theme-based translational model that now encompasses six industry partnerships, including this new collaboration with Celgene.  

August 19, 2015
Antibiotic Research UK will announce at its Annual General meeting its first research programme to tackle antibiotic resistant bacteria (superbugs)
July 9, 2015
Zevtera® (Ceftobiprole medocaril): the latest generation Cephalosporin with broad-spectrum of activity launches in the UK
May 14, 2015
Jim O’Neills Review on Antimicrobial Resistance launches their third interim report. Amongst the report’s recommendations is the creation of a $2 billion global fund to be spent over five years to assist organisations pay for their R&D on developing new antibiotics. Grants will be awarded from this fund, which will delink the reward side of antibiotic drug development from sales and should incentivise organisations to get back into the antibiotic development space. Global fund monies will be used to finance blue skies research into new antibiotics and diagnostics and encourage innovative partnerships at early development stages between academia and industry.
April 29, 2015
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
 
Ursula Theuretzbacher, the founder of the Centre for Anti-Infective Agents in Vienna, led the session, which gave a review of the research and development programmes from across some of the most innovative and nimble European biotech companies.

April 21, 2015
The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organisation that explores risk assessment, knowledge sharing and best practices in the fight against infectious disease – has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is done to develop new cures, rapid diagnostics and preventative measures to combat the spread of drug resistant diseases.

The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organisation that explores risk assessment, knowledge sharing and best practices in the fight against infectious disease – has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is done to develop new cures, rapid diagnostics and preventative measures to combat the spread of drug resistant diseases.

March 10, 2015
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced that the first patient has been enrolled in the Phase IIa “SAPHIR” clinical study of its lead product PQ912 at the Alzheimer Centre, VU Medical Centre (VUmc), Amsterdam.

Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced that the first patient has been enrolled in the Phase IIa “SAPHIR” clinical study of its lead product PQ912 at the Alzheimer Centre, VU Medical Centre (VUmc), Amsterdam.
 

March 23, 2014
On February 28th, Novartis joined the global rare disease community in recognition of Rare Disease Day by calling for a global exchange of ideas to deepen the understanding of rare diseases and help address a significant unmet medical need.

 

On February 28th, Novartis joined the global rare disease community in recognition of Rare Disease Day by calling for a global exchange of ideas to deepen the understanding of rare diseases and help address a significant unmet medical need.

 

February 8, 2013
A pioneering drug development team at the University of Aberdeen has received a

teaser

March 12, 2008
European cell-based assays markets face a tough challenge in identifying candidates in drug discovery, according to a consultancy report

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine